By Fineline Cube 
IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore‑based immune cell engineering and cell therapy company. The transaction brings MediSix’s proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO’s portfolio, strengthening its CAR‑T cell therapy pipeline for hard‑to‑treat T‑cell malignancies.
Deal Snapshot
| Item | Detail |
|---|---|
| Acquirer | IASO Biotherapeutics (China, cell therapy innovator) |
| Target | MediSix Therapeutics (Singapore) |
| Announcement Date | 13 Aug 2026 |
| Transaction Status | Completed |
| Strategic Rationale | Acquire PEBL platform technology and IASO107 lead asset for T‑cell malignancy CAR‑T cell therapy |
| Financial Terms | Not disclosed |
Target Profile – MediSix Therapeutics
- Founded: 2016, headquartered in Singapore
- Founder: Professor Dario Campana, an internationally renowned expert in translational immunology
- Core Focus: Addressing critical challenges in cell therapy for T‑cell malignancies
- Lead Asset: IASO107 (formerly PCART7), currently in clinical evaluation with leading international research hospitals
Technology Platform – PEBL (Protein Expression Blocker)
- Mechanism: Specifically blocks the expression of target proteins on the cell surface of CAR‑T cells, effectively reducing fratricide — the self‑destruction of therapeutic T cells that share antigens with target cancer cells.
- Key Advantage: Enables targeting of shared antigens between T cells and target cells, a long‑standing bottleneck in treating T‑cell malignancies.
- Research Integration: Combines in vitro and in vivo CAR‑T research, establishing exclusive technological barriers and competitive advantages across both hematologic malignancies and solid tumors.
Clinical Progress – IASO107
- Status: Ongoing clinical evaluation in collaboration with leading international research hospitals
- Early Readout: Encouraging signs of both efficacy and safety reported
- Prior Designation: Formerly known as PCART7
Market Impact & Outlook
- Differentiated Asset: The PEBL platform addresses one of the toughest problems in CAR‑T cell therapy — T‑cell malignancies, where conventional CAR‑T approaches fail due to fratricide.
- Pipeline Depth: The acquisition adds a clinically evaluated lead candidate (IASO107) rather than a preclinical asset, shortening IASO’s path to data readouts.
- Global Reach: MediSix’s international clinical collaborations extend IASO Biotherapeutics’ footprint beyond China into global research networks.
- Strategic Positioning: Combining IASO’s cell therapy development capabilities with MediSix’s proprietary engineering platform creates a differentiated player in hematologic malignancies and solid tumors.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the integration of MediSix Therapeutics, clinical development of IASO107, and potential applications of the PEBL platform. Actual results may differ due to risks including clinical outcomes, regulatory requirements, and competitive dynamics in cell therapy.-Fineline Info & Tech